Literature DB >> 8876029

Novel CCK-B receptor agonists: diketopiperazine analogues derived for CCK4 bioactive conformation.

J H Weng1, A Bado, C Garbay, B P Roques.   

Abstract

Recently, we proposed a CCK-B agonist bioactive conformation characterized by an 'S' shape of the peptidic backbone which was derived from structure-activity relationships and conformational analysis of CCK4 (Trp-Met-Asp-Phe-NH2) analogues. Using this template, we report here the synthesis of cyclic CCK4 analogues which contain, in place of the Trp-Met dipeptide, a diketopiperazine moiety resulting from a cyclization between Nle and N-substituted (D)Trp residues and coupled with a small linker to Asp-Phe-NH2. Some of these compounds displayed good affinities and selectivities for the CCK-B receptor. The results are discussed in terms of size, hydrophobicity and spatial orientation of the side-chains on the diketopiperazine ring. The most potent ligand exhibited potent and full CCK-B receptor agonist properties in promoting the hydrolysis of inositol phosphates (EC50 = 8 nM) in CHO cells, stably transfected with the rat brain CCK-B receptor. This compound was also shown to be a potent selective CCK-B/gastrin receptor agonist since, it increased gastric acid secretion measured in anesthetized rats on i.v. administration. These compounds provide a rigid template for the design of non-peptide CCK-B agonists, by modification of the remaining peptide moiety.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8876029     DOI: 10.1016/0167-0115(96)00065-1

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  1 in total

1.  New CCK2 agonists confirming the heterogeneity of CCK2 receptors: characterisation of BBL454.

Authors:  Bruno Bellier; Dominique Crété; Marie-Emmanuelle Million; Françoise Beslot; André Bado; Christiane Garbay; Valérie Daugé
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-10-08       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.